摘要 |
<p>Discloses the use of a functional fragment of a major royal jelly protein (MRJP) for preparation of a medicament for reducing inflammation in a cellular tissue in a patient; wherein the functional fragment has been isolated, enriched, synthesized, or recombinantly produced; wherein the functional fragment comprises 2 to 20 amino acids of the last 20 amino acids at the C-terminus of the protein; and wherein a lysine amino acid residue of the functional fragment has been chemically modified by methylglyoxal (MGO).</p> |